Uncategorized
BLOG: Supreme Court ‘pay-for-delay’ ruling hardly decides issue
On June 17, the Supreme Court handed down its decision in FTC v. Actavis, providing some clarity regarding the legal standard courts should apply to so-called “reverse payment” settlements. In these settlements, a brand drug company provides something of value to a generic drug company in order to resolve the parties’ patent litigation and clear the path for the generic product to come to market.